CompareMona.healthvsRetinAI

Mona.health is an AI retinal screening company for diabetic eye and retinal screening programs, flagging signs of eye disease to support screening and care routing.

1. Buyer fit: Diabetic eye and retinal screening programs are the core audience, with ophthalmology depth and primary care deployment central to its positioning.
2. Workflow boundary: Mona.health supports retinal screening and care routing rather than replacing ophthalmologists; every positive screen still requires specialist follow-up.
3. Implementation checks: Buyers should confirm regulatory clearance, camera and imaging hardware compatibility, downstream referral integration, and program reporting before launch.
4. Commercial approach: Pricing is sales-led and scoped per buyer rather than posted publicly; a focused pilot within one workflow is the cleanest way to test fit.

Overall, Mona.health fits teams seeking retinal screening detection that can support specialist follow-up and implementation.

RetinAI is an AI ophthalmology platform for eye care clinics and research programs, combining ophthalmic data management with analysis across screening workflows.

1. Clinical role: It supports retinal screening and care routing rather than replacing ophthalmologists, while specialist follow-up remains essential for every positive screen surfaced through the workflow.
2. Best-fit environment: Clinics and research programs gain value when ophthalmic data management and AI analysis align with established imaging workflows.
3. Implementation checks: Buyers should confirm regulatory clearance, camera and imaging hardware compatibility, downstream referral integration, and program reporting before launching diabetic eye screening across primary care sites.
4. Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, so value depends on imaging data workflow.

A focused pilot around one workflow is usually the clearest way to assess fit before wider adoption.